Abstract
Provision of a safe and secure supply of transfusible red blood cells (RBC) is a major global health challenge, and it has been proposed that manufactured RBC could help to alleviate the constraints of the current donor system. Several substantial challenges must be addressed for this approach to be feasible. At the most basic level, this relates to the large quantities of cells that are required: is there sufficient biological capacity, and is it possible to produce RBC using large-scale processes? While it has been demonstrated that, in principle, up to 5 units of RBC could be generated from a single donation of umbilical cord blood (UCB) hematopoietic stem cells, such yields are insufficient to supply demand and existing culture methods are unsuitable for large-scale manufacture. Given the capacity of the hematopoietic system in vivo, we reasoned that an optimized process should give rise to much larger quantities of RBC than previously reported. We successfully developed a robust ultra-high-yield RBC expansion process capable of producing over 500 units of RBC per UCB donation using fully defined culture medium. We obtained near-pure populations of reticulocytes with an enucleation frequency of >90%, mean cell hemoglobin content of 30.8 pg/cell, and mean cell volume of 133 fL. We also show that RBC can be efficiently produced in agitated bioreactor systems, demonstrating that no fundamental barriers exist to the manufacture of RBC using large-scale approaches.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.